Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a diabetes drug also mend hearts? new study in kazakhstan investigates

NCT ID NCT07303556

Disease control Sponsor: Nazarbayev University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a dual GIP/GLP-1 drug (a type of diabetes medication) in 120 adults in Kazakhstan who have both chronic heart failure and type 2 diabetes. Participants take the drug for 40 weeks and have regular heart tests, blood work, and genetic checks. The goal is to see if the drug improves heart function, blood sugar, and weight, and to understand how genetics affect response.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 120 people

The number the study aims to enrol. It can still change while the study runs.

Started

Dec 2024

Expected to finish

Nov 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Chronic heart failure with preserved ejection fraction (left ventricular ejection fraction not ≤ 45%) * Type 2 diabetes mellitus (T2DM) with HbA1c level between ≥7.0% and ≤10.5% * Ongoing treatment for T2DM (e.g., metformin and/or sulfonylureas, or basal insulin therapy) * Stable body weight (±5%) for at least 3 months prior to screening * Body mass index (BMI) ≥ 25 kg/m² * Possible inclusion of patients with chronic pancreatitis in remission * Aged 18 years or older, and not older than 75 years * Both male and female participants Exclusion Criteria: * Type 1 diabetes mellitus * Exacerbation of chronic pancreatitis * Acute pancreatitis * Proliferative diabetic retinopathy, diabetic maculopathy, or non-proliferative diabetic retinopathy * History of bariatric (weight-loss) surgery or conditions associated with delayed gastric emptying * Acute or chronic hepatitis * Chronic kidney disease (CKD) with estimated glomerular filtration rate (eGFR) \< 45 ml/min/1.73 m² * Myocardial infarction or stroke within the past 2 months * Medullary thyroid carcinoma or multiple endocrine neoplasia type 2 (MEN2) in the participant or a first-degree relative * Use of any other antidiabetic medications (except metformin and/or sulfonylureas and basal insulin) within the past 3 months * Use of weight loss medications, including over-the-counter drugs, within the past 3 months * History of significant active or unstable major depressive disorder (MDD) or other severe psychiatric disorders within the past 2 years * Healthy individuals (no cardiovascular or metabolic disease)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Arterial hypertension are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

diastolic heart failure essential hypertension heart failure hypertensive disorder type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Arterial hypertension Diabete type 2 Heart failure

Contacts and locations

Locations

  • PI "National Laboratory Astana", Nazarbayev University

    Astana, Kazakhstan, 010000, Kazakhstan

More trials for these conditions

Other studies related to the condition(s) this trial covers.